(Q36909282)

17 August 2017

1 reference

title

The economics of temozolomide in brain cancer (English)

1 reference

17 August 2017

1 reference

1 reference

Ralph Crott

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1923-1929

1 reference

A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Optimal role of temozolomide in the treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Recent advances in the treatment of malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

Economics of new oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1923

10.1517/14656566.8.12.1923

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference